ABBV insider trading
NYSE HealthcareAbbVie Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About AbbVie Inc.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. AbbVie Inc. has strategic partnership with OSE Immunotherapeutics. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Company website: www.abbvie.com
ABBV insider activity at a glance
FilingIQ has scored 1,284 insider transactions for ABBV since Feb 17, 2015. The most recent filing in our index is dated May 8, 2026.
Across the full history, 20 open-market purchases
and 393 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on ABBV insider trades is 64.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest ABBV Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding ABBV
Politicians who have traded ABBV
Frequently asked
- How many insider trades does FilingIQ track for ABBV?
- FilingIQ tracks 1,284 Form 4 insider transactions for ABBV (AbbVie Inc.), covering filings from Feb 17, 2015 onwards. 78 of those were filed in the last 90 days.
- Are ABBV insiders net buyers or net sellers?
- Across the full Form 4 history for ABBV, 20 transactions (2%) were open-market purchases and 393 (31%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does ABBV insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is ABBV in?
- AbbVie Inc. (ABBV) is classified in the Healthcare sector, specifically Drug Manufacturers - General, with a current market capitalisation of $396.69B.
Methodology & sources
Every ABBV insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.